Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

Exclusion Criteria

• •1. Has disease that is suitable for therapy administered with curative intent.
• •2. Ongoing treatment with another anticancer agent indicated for the malignancy for which the subject is enrolling into the study (excluding adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive prostate cancer).
• •3. History of cardiomyopathy, unstable angina within prior 6 months, myocardial infarction within prior 6 months, cerebrovascular attack within prior 6 months, history of New York Heart Association grade III or greater congestive heart failure, or current serious cardiac arrhythmia requiring medication.
• •4. Non-tolerable Grade 2 or ≥ Grade 3 neuropathy or evidence of unstable neurological symptoms within 4 weeks of Cycle 1 Day 1.
• •5. Major surgery, other than diagnostic surgery, within 14 days prior to Cycle 1 Day 1, without complete recovery.
• •6. Active, uncontrolled bacterial, viral or fungal infections requiring systemic therapy.
• •7. Other protocol defined exclusion may apply